showcase-image-oncomine

The Ion Torrent Oncomine Myeloid MRD assays (RUO) on the Ion GeneStudio S5 System offer a complete next-generation sequencing (NGS) solution for myeloid MRD detection. Highly sensitive NGS, based on Ion AmpliSeq HD technology, which enables a limit of detection as low as 0.05% allele frequency.

Request quote   Download infographic   View video

 Poster: Analytical performance of a novel next-generation sequencing assay for myeloid MRD

A DNA and an RNA assay are available to cover a wide range of myeloid MRD targets, including key single nucleotide variants (SNVs), insertions and deletions (indels), tandem duplications, and key gene fusions. The carefully curated targets on the panel are relevant for all major types of myeloid neoplasms, including acute myeloid leukemias (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN) samples.

Key features:

  • Comprehensive panels—a DNA and an RNA assay that helps you assess a wide range of variants associated myeloid MRD, including SNVs, indels, gene fusions, and tandem duplications
  • Fast and simple workflow—using the Ion GeneStudio S5 system, have results in 2–3 days with only ~2 hours of hands-on time required
  • High sensitivity—error correcting NGS with Ion AmpliSeq HD technology helps provide a low limit of detection (down to 0.05% allele frequency) required for MRD analysis
  • Optional chimerism analysis—an optional micro-haplotye panel enables sensitive assessment of donor-recipient mixtures with a limit of detection (LOD) as low as 0.2% AF
  • Integrated informatics—an analytically validated informatics pipeline and reporting solution that includes longitudinal tracking helps simplify the interpretation of results
     

Customer webinar

tandon2

Genomic profiling from initial assessment to detection of MRD: How NGS can rapidly deliver key insights for myeloid neoplasms

Hear Dr. Bevan Tandon review ongoing research in his lab using the Oncomine Myeloid Assay GX and share recent analytical data using the Oncomine Myeloid MRD assays for highly sensitive MRD detection.

Watch the webinar ›


Gene content summary

DNA assay

RNA assay

33 genes, including 2 full genes and FLT3-ITDs42 fusion driver genes
1,255 hotspots990 unique fusions
Optional 22-amplicon micro-haplotype panel for chimerism analysis 6 genes with exon splicing variants
 5 expression control genes


Gene list

DNA assay

RNA assay

Target genes

Fusion driver genes

Expression controls

Exon splicing variants

ABL1

FLT3**

NRAS

TP53*

ABL1

ETV6

 

NTRK3

RET

ABL1

KMT2A

ASXL1

GATA2

PHF6

U2AF1

ABL2

FGFR1

MECOM

NUP214

RUNX1

GUSB

RUNX1

BCOR

IDH1

PTPN11

WT1

ALK

FUS

MLLT10

NUP98

TAL1

PSMB2

NOTCH1

BRAF

IDH2

RUNX1

 

BCL2

GLIS2

MRTFA (MKL1)

PAX5

TCF3

PUM1

ETV6

CALR

JAK2

SETBP1

 

BRAF

HMGA2

MYBL1

PDGFRA

TCF4

TRIM27

IKZF1

CBL

KIT

SF3B1

 

CCND1

JAK2

MYH11

PDGFRB

TFE3

 

NTRK1

CEBPA*

KRAS

SH2B3

 

CREBBP

KAT6A (MOZ)

NOTCH1

RARA

ZNF384

 

 

CSF3R

MPL

SRSF2

 

CSF1R

KAT6B

NTRK1

RARB

 

 

 

DNMT3A

MYD88

STAG2

 

EGFR

KMT2A (includes PTD)

NTRK2

RARG

 

 

 

EZH2

NPM1

TET2

 

 

 

 

 

 

 

 

* Full gene coverage.
** Exon 14 and 15, includes FLT3-ITDs and TKD mutations
 

Workflow


Learn more

To see customer presentations, scientific posters, and learn more about these assays, visit oncomine.com 


Request a quote

Would you like to speak with a representative about these products?

Request a quote


Ordering information

仅供科研使用,不可用于诊断目的。